This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Rossouw JE et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321–333
McNeil C (2007) Breast cancer decline mirrors fall in hormone use, spurs both debate and research. J Natl Cancer Inst 99: 266–267
Cumming RG et al. (1997) Calcium intake and fracture risk: results from the study of osteoporotic fractures. Am J Epidemiol 145: 926–934
Cranney A et al. (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23: 570–578
Acknowledgements
The synopsis was written by Rosalind Archer, Editorial Assistant, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Black, D., Rosen, C. Is risedronate or alendronate more effective at preventing nonvertebral fractures in women with osteoporosis?. Nat Rev Rheumatol 3, 378–379 (2007). https://doi.org/10.1038/ncprheum0530
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0530
This article is cited by
-
Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis
Aging Clinical and Experimental Research (2010)
-
Is risedronate or alendronate more effective at preventing nonvertebral fractures in women with osteoporosis?
Nature Clinical Practice Rheumatology (2007)